Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308.

View in: PubMed

subject areas

Adult
Anti-Obesity Agents
Cardiovascular Diseases
Delayed-Action Preparations
Diabetes Mellitus
Double-Blind Method
Drug Combinations
Female
Fructose
Humans
Incidence
Intention to Treat Analysis
Least-Squares Analysis
Male
Metabolic Diseases
Middle Aged
Obesity
Overweight
Patient Dropouts
Phentermine
Time
Weight Loss

authors with profiles

W. Timothy Garvey